BTCC / BTCC Square / Global Cryptocurrency /
Roivant Sciences Stock Surges on Positive Late-Stage Clinical Results

Roivant Sciences Stock Surges on Positive Late-Stage Clinical Results

Global Cryptocurrency
Release Time:
2025-09-17 18:42:02
0
BTCCSquare news:

Roivant Sciences (ROIV) shares jumped 11.4% after announcing promising phase 3 trial data for brepocitinib, a potential treatment for dermatomyositis. The drug met all primary and secondary endpoints with a favorable safety profile, positioning it as a potential blockbuster in rare autoimmune diseases.

Priovant Therapeutics, 75%-owned by Roivant, plans to seek FDA approval by mid-2026. With only one currently approved therapy for the 50,000 U.S. patients affected, brepocitinib could capture significant market share as the sole oral treatment in late-stage development.

Articles on this site are sourced from public networks or curated by AI for informational purposes only and do not represent BTCC’s views. Original rights belong to the respective authors. For copyright concerns, please contact [email protected]. BTCC assumes no liability for the accuracy, timeliness, or completeness of this information, and disclaims all liability arising from reliance on such content. This content is for reference only and should not be taken as investment, legal, or commercial advice.

|Square

Get the BTCC app to start your crypto journey

Get started today Scan to join our 100M+ users